(NASDAQ: XOMA) Xoma Royalty's forecast annual revenue growth rate of 14.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.93%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.99%.
Xoma Royalty's revenue in 2026 is $52,149,000.On average, 7 Wall Street analysts forecast XOMA's revenue for 2026 to be $773,569,739, with the lowest XOMA revenue forecast at $602,866,500, and the highest XOMA revenue forecast at $1,150,526,492. On average, 4 Wall Street analysts forecast XOMA's revenue for 2027 to be $740,043,423, with the lowest XOMA revenue forecast at $612,307,682, and the highest XOMA revenue forecast at $867,564,861.
In 2028, XOMA is forecast to generate $988,812,021 in revenue, with the lowest revenue forecast at $713,470,007 and the highest revenue forecast at $1,271,404,577.